CMSC 2024: Navigating Treatment Switches and Aging in MS

Donald Negroski, MD, shared thoughts on retrospective data assessing patients with multiple sclerosis who switched from S1P-modulating agents to ozanimod, another approved disease-modifying therapy.

In this conversation, Negroski provides commentary on the role of lymphocyte counts and specifically a study evaluating changes in these counts for patients switching between dimethyl and diroximel fumarates.

Negroski discussed some of the takeaways from an analysis of patients with stable MS who chose to switch from natalizumab to other, more moderate-efficacy oral disease-modifying therapies.

In this segment, Negroski comments on the realism behind wearing off effect of treatments, specifically ocrelizumab, and how clinicians may work around some of these issues.